UBT251
Sponsors
The United Bio-Technology (Hengqin) Co., Ltd., Novo Nordisk A/S
Conditions
Chronic Kidney DiseaseDiabetes Mellitus, Type 2Drug Drug Interaction (DDI)Metabolic Dysfunction-associated Steatohepatitis (MASH)ObesityObesity &Amp; OverweightObstructive Sleep ApneaObstructive Sleep Apnea, Obesity
Phase 1
A Research Study on How UBT251 Affects Levels of Midazolam, Caffeine and Warfarin in the Blood of Participants With Excess Body Weight
RecruitingNCT07710768
Start: 2026-07-15End: 2027-04-07Target: 44Updated: 2026-08-18
A Research Study Looking Into How UBT251 Works With Birth Control Tablets and Emptying of the Stomach in Women With Excess Body Weight Not Able to Become Pregnant
RecruitingNCT07710729
Start: 2026-07-17End: 2027-04-27Target: 40Updated: 2026-08-25
Phase I Drug-Drug Interaction Study of UBT251 Injection in Participants With Overweight or Obesity
RecruitingNCT07785934
Start: 2026-05-27End: 2026-12-01Target: 48Updated: 2026-08-25
Phase 2
UBT251 Injection Phase II Clinical Study (CKD)
RecruitingNCT07134335
Start: 2025-09-01End: 2030-07-11Target: 180Updated: 2025-11-25
A Study of UBT251 in Participants With Metabolic Dysfunction-Associated Steatohepatitis (MASH)
RecruitingNCT07145151
Start: 2025-09-30End: 2027-08-31Target: 156Updated: 2025-11-20
A Research Study on How Well Different Doses of the Medicine UBT251 Help People Living With Overweight or Obesity
RecruitingNCT07395687
Start: 2026-02-02End: 2027-02-18Target: 333Updated: 2026-04-21
A Research Study Comparing How Well Different Doses of the Medicine UBT251 Lower Blood Sugar in People With Type 2 Diabetes
RecruitingNCT07668388
Start: 2026-06-22End: 2027-11-15Target: 300Updated: 2026-08-10